Journey Medical (DERM) Q3 2026 earnings review
Journey Medical grows rosacea drug sales, but unpaid bills drain cash
Journey Medical's new rosacea pill Emrosi now brings in nearly half of revenue while its older skin drugs shrink. Total sales rose 8% from a year ago to $19 million, as an 84% jump in Emrosi offset an 18% drop across the rest of the product lineup by our math. Chief executive Claude Maraoui pointed to rising prescription demand and wider health plan coverage, while a one-time $1.7 million vendor settlement pushed the company back into a small operating loss.
| Total revenue | $19.0M +8% from a year ago |
|---|---|
| Emrosi rosacea sales | $9.0M +84% from a year ago (~40,000 scripts) |
| Operating result | -$0.5M +$1.2M excluding $1.7M vendor settlement |
| Cash on hand | $22.3M down from $25.6M as unpaid bills rose $11.1M |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because Emrosi's prescription climb and lower underlying overhead were countered by a cash drain from unpaid customer bills. Setting aside the legal settlement, operating profit reached $1.2 million by our math and resolved a standing vendor dispute. The bad news: unpaid bills jumped by $11 million to $47 million, pulling cash down to $22 million just as $7.5 million of debt comes due within a year.
The question now is whether wider insurance coverage can lift the cash collected per Emrosi prescription before loan repayments start in February 2027. Either new health plan contracts convert unpaid wholesaler bills into cash and lift net price above $225 per script, or heavy discount coupon use and working-capital needs force a stock offering. The fourth-quarter 10-Q cash flow statement and net price per script will tell.
🐂 Bull Case
Emrosi Reaches Nearly Half of Total Sales
Emrosi, Journey Medical's oral capsule for treating the skin condition rosacea, now brings in nearly half of the dermatology drugmaker's revenue. Chief executive Claude Maraoui attributed the 84% sales jump from a year ago to "growth in prescription demand and continued improvement in the mix of prescriptions reimbursed by health plans".
- Emrosi net revenue: $9.0 million, up from $8.1 million last quarter and $4.9 million a year ago
- Total prescriptions: about 40,000, up 11% from 36,000 in the second quarter
- Net revenue per prescription: about $225 by our math, compared with $224 last quarter and $209 in the first quarter
The company expanded its sales force and added national health plan coverage during the summer. Those steps kept prescription volume climbing, while net revenue per prescription held steady at $225 by our math after two quarters of gains. "The number of unique prescribers writing for Emrosi® increased again during the third quarter," Maraoui said.
What to watch: Emrosi net revenue per prescription in the fourth quarter, when the August national health plan addition takes fuller effect. A move above $230 would show that new insurance coverage is reducing the drugmaker's reliance on patient discount coupons.
Underlying Operating Profit Improved Without One-Time Charge
Journey Medical reported a $0.5 million operating loss, a step back from its first operating profit of $0.5 million in the second quarter. However, selling, general and administrative expenses (overhead and sales costs) included a one-time $1.7 million charge for the "resolution of a dispute with a former vendor", the company said.
Without that legal settlement, overhead and sales costs fell to 57.2% of revenue from 68.4% a year ago by our math, a drop of 11.2 percentage points. Lower Emrosi launch spending drove the savings, lifting underlying operating profit to $1.2 million by our math and clearing a standing legal risk.
What to watch: selling, general and administrative expenses in the fourth quarter, the first full period with the expanded sales team. Keeping that line near 58% of revenue without one-off charges would keep operating profit positive.
🐻 Bear Case
Unpaid Customer Bills Consumed Cash
Chief executive Claude Maraoui said that with over $22 million in cash, the dermatology group is well-positioned to advance its mission. Yet the balance sheet still carries "substantial doubt expressed about our ability to continue as a going concern", Journey Medical noted in its risk disclosures, and cash fell during the quarter.
- Cash and cash equivalents: $22.3 million, down $3.3 million from $25.6 million in June
- Accounts receivable (unpaid customer bills): $47.4 million, up $11.1 million in three months and up 164% from a year ago by our math
- Short-term debt due within 12 months: $7.5 million, up from $5.0 million in June as February 2027 loan repayments approach
Unpaid bills now equal two and a half quarters of total revenue because drug wholesalers take time to pay as prescriptions grow. Even if you set aside the $1.7 million vendor settlement, the working-capital buildup drained cash just as $2.5 million quarterly debt repayments draw closer.
What to watch: accounts receivable collection and operating cash flow in the quarterly 10-Q filing. Cash will keep falling until collections from drug distributors catch up with reported revenue.
Older Skin Drugs Keep Shrinking
Journey Medical markets nine branded dermatology drugs, but its older products are losing ground to generic competitors. Total revenue growth slowed to 7.6% from a year ago, down from 23.3% in the second quarter, because the rest of the portfolio shrank alongside lower licensing and supply income.
Subtracting Emrosi's $9.0 million from total product sales leaves $9.9 million for the other eight drugs by our math. That is down 18.1% from $12.1 million a year ago, though steady against $9.7 million in the second quarter. Emrosi now carries the entire growth of the business.
What to watch: individual product sales for Qbrexza, its medicated cloth for excessive sweating, in the upcoming 10-Q filing. A drop below $4.8 million in its peak summer quarter would show that older products are eroding faster than Emrosi can offset.
Risks this quarter didn't answer
Three standing concerns from prior quarters received no new detail in the earnings release and depend on the conference call or the quarterly 10-Q filing.
- Formal financial outlook: absent again from the release, leaving no full-year revenue or profit target.
- Coupon and rebate provisions: gross-to-net price deductions are only published in the 10-Q footnotes, which will show whether discount coupon costs stopped doubling.
- Voting control and share dilution: parent company Fortress Biotech retains a voting majority, while basic share count rose 12.5% from a year ago to 28.1 million.
💲 Other KPIs
Gross margin — the share of sales left after manufacturing and royalty costs — rose 1.6 percentage points from 67.4% a year ago and 2.2 points from the second quarter. The shift toward higher-margin Emrosi prescriptions lifted the rate to its highest reading since launch.
Stock on hand fell 4.7% from $8.16 million in June and is down 19.2% from $9.62 million at the end of 2025. The dermatology company is working down earlier inventory builds as Emrosi prescription volume scales.
Weighted average basic shares rose 12.5% from 25.0 million a year ago and 2.1% from 27.5 million in the second quarter. Past stock sales and employee share grants continued to expand the share base, though the year-over-year increase slowed from 18.0% last quarter.
🔮 Guidance
Unchanged. Journey Medical issued no new outlook table in the release, after stating in previous quarters that it aimed to keep EBITDA — earnings before interest, taxes, depreciation and amortization — positive in the second half of 2026. Third-quarter EBITDA was $0.43 million, down from $1.42 million in the second quarter because of the $1.7 million vendor settlement, or $2.18 million excluding that charge by our math.
❓ Key Questions
Why did unpaid customer bills jump to $47.4 million?
Accounts receivable grew by $11.1 million in the third quarter while total revenue rose by just $0.46 million from the second quarter. Investors need to know payment terms with drug wholesalers and when those receivables will turn into cash.
How did Qbrexza perform during its peak summer quarter?
Product sales outside Emrosi fell 18% from a year ago by our math, and the release did not break out individual older brands. The third quarter is seasonally strongest for Qbrexza, making its 10-Q revenue number the test of legacy brand stability.
How will Journey Medical fund the 2027 debt repayments?
Short-term debt rose to $7.5 million as $2.5 million quarterly principal payments begin in February 2027, while cash slipped to $22.3 million. Management has not said whether it plans to refinance the loan or issue stock under its shelf registration.
Why did Emrosi revenue per prescription stall at $225?
By our math, Emrosi net revenue per prescription was $225 in the third quarter versus $224 in the second, despite chief executive Claude Maraoui citing a better mix of reimbursed prescriptions. What share of patients still relies on copay discount cards?